[1]汪钦生,邵 敏,姜 涛.绝经后妇女中骨质疏松患者血清钙磷、骨代谢指标与BMD的关系[J].医学信息,2019,32(04):1-4.[doi:10.3969/j.issn.1006-1959.2019.04.001]
　WANG Qin-sheng,SHAO Min,JIANG Tao.Relationship between Serum Calcium,Phosphorus and Bone Metabolism Markers and BMD in Postmenopausal Women with Osteoporosis[J].Journal of Medical Information,2019,32(04):1-4.[doi:10.3969/j.issn.1006-1959.2019.04.001]
点击复制

绝经后妇女中骨质疏松患者血清钙磷、骨代谢指标与BMD的关系()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
32卷
期数:
2019年04期
页码:
1-4
栏目:
出版日期:
2019-02-15

文章信息/Info

Title:
Relationship between Serum Calcium,Phosphorus and Bone Metabolism Markers and BMD in Postmenopausal Women with Osteoporosis
文章编号:
1006-1959（2019）04-0001-04
作者:
汪钦生; 邵 敏; 姜 涛
（广州中医药大学第三附属医院关节骨科，广东 广州 510240）
Author(s):
WANG Qin-sheng; SHAO Min; JIANG Tao
(Department of Orthopaedics,the Third Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine,Guangzhou 510240,Guangdong,China)
关键词:
骨质疏松症; 骨代谢指标; 骨密度
Keywords:
Osteoporosis; Bone turnover markers; Bone mineral density
分类号:
R681
DOI:
10.3969/j.issn.1006-1959.2019.04.001
文献标志码:
A
摘要:
目的 探讨绝经后妇女骨质疏松患者血清钙磷、骨代谢指标与骨密度（BMD）的相关性。方法 应用双能X线吸收法对86例绝经后妇女进行骨密度检查，根据骨密度分为骨质疏松组63例和正常组23例。分别检测两组血清Ca、P、β-胶原降解产物（β-CrossLaps）、N端骨钙素（N-MID osteocalcin）、Ⅰ型胶原N端前肽（PⅠNP）指标，并进行比较。进一步根据年龄分为4组：≤59岁3例设为A组，60~69岁10例设为B组，70~79岁36例设为C组，≥80岁37例设为D组，分析各组骨代谢指标与BMD的相关性。结果 ①骨质疏松组的年龄为（78.21±7.57）岁，高于正常组的（74.35±7.15）岁，BMD低于正常组（P＜0.01）；②骨质疏松组β-CrossLaps、N-MID、PINP三项指标均高于正常组，但差异无统计学意义（P＞0.05），钙磷水平无明显差别（P＞0.05）；③β-CrossLaps在A组和C组与BMD呈负相关（r=-0.492、-0.035，P＜0.05），在B组和D组呈现正相关（r=0.318、0.058，P＜0.05）；N-MID在各组均与BMD呈负相关（r=-0.972、-0.382、-0.001、-0.153，P＜0.05）；PINP在C组与BMD呈正相关（r=0.052，P＜0.05），在A组、B组、D组与BMD呈负相关（r=-0.991、-0.515、-0.187，P＜0.05）；血清钙Ca在各组均与BMD呈正相关（r=0.362、0.307、0.105、0.137，P＜0.05）；P在A组、C组、D组与BMD呈负相关（r=-0.530、-0.047、-0.029，P＜0.05），而在B组与BMD呈正相关（r=0.020，P＜0.05）。结论 β-CrossLaps、N-MID、PINP与BMD存在密切的关系，应联合用于骨质疏松症的诊治及病情监测。
Abstract:
Objective To investigate the correlation between serum calcium, phosphorus and bone metabolism markers and bone mineral density in postmenopausal women with osteoporosis. Methods A total of 86 postmenopausal women in our hospital were examined for bone mineral density by dual-energy X-ray absorptiometry. According to bone mineral density, 63 patients were divided into osteoporosis group and 23 patients in normal group. Serum Ca, P, β-collagen degradation products (β-CrossLaps), N-terminal osteocalcin (N-MID) and type I collagen N-terminal propeptide (PINP) were measured and compared. According to the age, the patients were divided into 4 groups: ≤59 years old, 3 cases were set to group A, 60 to 69 years old, 10 cases were set to group B, 70 to 79 years old, 36 cases were set to group C, and ≥80 years old, 37 cases were set to group D. The correlation between bone metabolic markers and bone mineral density was analyzed. Results ①The age of osteoporosis group was (78.21±7.57) years old, higher than that of normal group (74±7.15) years old, bone mineral density was lower than normal group (P<0.01);②Osteoporosis group β-CrossLaps, N- MID and PINP were higher than the normal group, but the difference was not statistically significant (P>0.05). There was no significant difference in calcium and phosphorus levels (P>0.05). ③β-CrossLaps was negatively correlated with BMD in group A and C. (r=-0.492, -0.035, P<0.05), there was a positive correlation between group B and group D (r=0.318, 0.058, P<0.05); N-MID was negatively correlated with BMD in each group (r= -0.972, -0.382, -0.001, -0.153, P<0.05); PINP was positively correlated with BMD in group C (r=0.052, P<0.05), and negatively correlated with BMD in group A, B, and D ( r=-0.991, -0.515, -0.187, P<0.05); serum calcium was positively correlated with BMD in each group (r=0.362, 0.307, 0.105, 0.137, P<0.05); P in group A, group C, group D was negatively correlated with BMD (r=-0.530, -0.047, -0.029, P<0.05), while there was a positive correlation between group B and BMD (r=0.020, P<0.05). Conclusion β-CrossLaps, N-MID, PINP and BMD are closely related and should be used in the diagnosis and treatment of osteoporosis and disease monitoring.

参考文献/References:


[1]Ensrud KE,Crandall CJ.Osteoporosis[J].Ann Intern Med,2017,167(3):Itc17-Itc32.
[2]Camacho PM,Petak SM,Binkley N,et al.American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis-2016[J].Endocr Pract,2016,22(Suppl 4):1-42.
[3]Tu KN,Lie JD,Wan CKV,et al.Osteoporosis:A Review of Treatment Options[J].P T,2018,43(2):92-104.
[4]Eastell R,Szulc P.Use of bone turnover markers in postmenopausal osteoporosis[J].Lancet Diabetes Endocrinol,2017,5(11):908-923.
[5]中华医学会骨质疏松和骨矿盐疾病分会.原发性骨质疏松症诊疗指南(2017)[J].中华内分泌代谢杂志,2017,33(10):890-913.
[6]Anonymous.Management of osteoporosis in postmenopausal women:2010 position statement of The North American Menopause Society[J].Menopause-the Journal of the North American Menopause Society,2010,17(1):25-54.
[7]Cosman F,Beur SJD,Leboff MS,et al.Clinician's Guide to Prevention and Treatment of Osteoporosis[J].Compr Ther,2014,25(10):2359-2381.
[8]Recker RR,Fernando M,Sophia IS,et al.Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis[J].J Bone Miner Res,2009,24(8):1358-1368.
[9]Koivula MK,Risteli L, Risteli J.Measurement of aminoterminal propeptide of type I procollagen (PINP) in serum[J].Clinical Biochemistry,2012,45(12):920-927.
[10]Samuel V,Cyrus C,Richard E,et al.International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine position on bone marker standards in osteoporosis[J].Clinical Chemistry & Laboratory Medicine Cclm,2011,49(8):1271-1274.
[11]Wichers M,Schmidt E,Bidlingmaier F,et al.Diurnal rhythm of CrossLaps in human serum[J]. Clinical Chemistry,1999,45(10):1858-1860.
[12]赵玉玺,张彬,湛梅圣,等.金天格胶囊对骨质疏松性骨折大鼠BGP、TRACP表达的影响[J].中国骨质疏松杂志,2014(11):1302-1305.
[13]刘菊,梅群超,罗娜,等.老年女性骨质疏松症患者血清骨标志物和E2含量的变化及临床意义[J].实用老年医学,2012,26(6):470-471.
[14]赵和平.P1NP、β-Crosslaps与绝经老年女性骨质疏松相关性研究[J].陕西医学杂志,2014(7):865-866.

相似文献/References:

[1]冯欢欢.骨质疏松症中医理论研究的文献计量学分析[J].医学信息,2022,35(16):28.[doi:10.3969/j.issn.1006-1959.2022.16.006]
　FENG Huan-huan.Bibliometric Analysis of TCM Theoretical Research on Osteoporosis[J].Journal of Medical Information,2022,35(04):28.[doi:10.3969/j.issn.1006-1959.2022.16.006]
[2]李 红,孔令泉,吴凯南.乳腺癌相关骨质疏松症的发病机制及防治[J].医学信息,2020,33(07):36.[doi:10.3969/j.issn.1006-1959.2020.07.012]
　LI Hong,KONG Ling-quan,WU Kai-nan.Pathogenesis and Prevention of Breast Cancer Associated Osteoporosis[J].Journal of Medical Information,2020,33(04):36.[doi:10.3969/j.issn.1006-1959.2020.07.012]
[3]刘 纳,李玉兰,许明芳,等.2型糖尿病临床期肾病与骨密度及骨代谢标记物的相关性研究[J].医学信息,2020,33(08):70.[doi:10.3969/j.issn.1006-1959.2020.08.023]
　LIU Na,LI Yu-lan,XU Ming-fang,et al.Study on the Relationship Between Bone Mineral Density and Bone Metabolism Markers in Stage IV Nephropathy of Type 2 Diabetes Mellitus[J].Journal of Medical Information,2020,33(04):70.[doi:10.3969/j.issn.1006-1959.2020.08.023]
[4]石耀武,陶宝琛,张宏蕾.西安地区骨质疏松症的影响因素及中医证型分布[J].医学信息,2020,33(11):136.[doi:10.3969/j.issn.1006-1959.2020.11.043]
　SHI Yao-wu,TAO Bao-chen,ZHANG Hong-lei.Influencing Factors of Osteoporosis in Xi’an and Distribution of TCM Syndromes[J].Journal of Medical Information,2020,33(04):136.[doi:10.3969/j.issn.1006-1959.2020.11.043]
[5]张 宁,夏晓黎,王亚锋,等.慢性阻塞性肺疾病合并骨质疏松症危险因素的Meta分析[J].医学信息,2022,35(24):108.[doi:10.3969/j.issn.1006-1959.2022.24.020]
　ZHANG Ning,XIA Xiao-li,WANG Ya-feng,et al.Meta-analysis of Risk Factors for Chronic Obstructive Pulmonary Disease Complicated with Osteoporosis[J].Journal of Medical Information,2022,35(04):108.[doi:10.3969/j.issn.1006-1959.2022.24.020]
[6]米尔阿地力·麦麦提依明,阿卜杜萨拉木·亚克甫,沈志敏.骨质疏松对全膝关节置换术后康复的影响[J].医学信息,2021,34(09):99.[doi:10.3969/j.issn.1006-1959.2021.09.026]
　Mieradili·Maimaitiyiming,Abudusalamu·Yakepu,SHEN Zhi-min.Effect of Osteoporosis on Rehabilitation After Total Knee Arthroplasty[J].Journal of Medical Information,2021,34(04):99.[doi:10.3969/j.issn.1006-1959.2021.09.026]
[7]周奕良,毛国庆.基于网络药理学和分子对接技术探讨淫羊藿苷治疗骨质疏松症的作用机制[J].医学信息,2023,36(05):29.[doi:10.3969/j.issn.1006-1959.2023.05.005]
　ZHOU Yi-liang,MAO Guo-qing.The Mechanism of Icariin in the Treatment of Osteoporosis Based on Network Pharmacology and Molecular Docking Technology[J].Journal of Medical Information,2023,36(04):29.[doi:10.3969/j.issn.1006-1959.2023.05.005]
[8]李泽芹.降钙素联合阿仑膦酸盐治疗原发性骨质疏松症有效性评价[J].医学信息,2021,34(17):154.[doi:10.3969/j.issn.1006-1959.2021.17.041]
　LI Ze-qin.Evaluation of the Effectiveness of Calcitonin Combined with Alendronate Sodium in the Treatment of Primary Osteoporosis[J].Journal of Medical Information,2021,34(04):154.[doi:10.3969/j.issn.1006-1959.2021.17.041]
[9]王彦金,周英杰,黄 勇.单、双侧椎弓根入路经皮椎体成形术治疗骨质疏松型椎体压缩骨折的对比研究[J].医学信息,2023,36(08):127.[doi:10.3969/j.issn.1006-1959.2023.08.027]
　WANG Yan-jin,ZHOU Ying-jie,HUANG Yong,et al.Comparative Study of Unilateral and Bilateral Pedicle Approach Percutaneous Vertebroplasty in the Treatment of Osteoporotic Vertebral Compression Fractures[J].Journal of Medical Information,2023,36(04):127.[doi:10.3969/j.issn.1006-1959.2023.08.027]
[10]朱道信,罗志环,陈少健,等.唑来膦酸联合骨化三醇对骨质疏松症患者骨密度及骨代谢相关指标的影响[J].医学信息,2021,34(23):162.[doi:10.3969/j.issn.1006-1959.2021.23.049]
　ZHU Dao-xin,LUO Zhi-huan,CHEN Shao-jian,et al.Effect of Zoledronic Acid Combined with Calcitriol on Bone Mineral Density and Bone Metabolism in Patients with Osteoporosis[J].Journal of Medical Information,2021,34(04):162.[doi:10.3969/j.issn.1006-1959.2021.23.049]

更新日期/Last Update: 2019-03-07